CN102872122A - Application of Houttuynoid B in medicament for treating pancreatic cancer - Google Patents
Application of Houttuynoid B in medicament for treating pancreatic cancer Download PDFInfo
- Publication number
- CN102872122A CN102872122A CN2012104194435A CN201210419443A CN102872122A CN 102872122 A CN102872122 A CN 102872122A CN 2012104194435 A CN2012104194435 A CN 2012104194435A CN 201210419443 A CN201210419443 A CN 201210419443A CN 102872122 A CN102872122 A CN 102872122A
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- pancreatic cancer
- medicament
- application
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of Houttuynoid B in preparing a medicament for treating pancreatic cancer, and belongs to the technical field of new use of medicament. Houttuynoid B is found to have an obvious inbibitional effect on the growth of human pancreatic cancer cell lines PANC-1 and BXPC through MTT (Methyl Thiazolyl Ternzolinm) anticancer activity evaluation in vitro. Therefore, Houttuynoid B can be used for preparing the anti-pancreatic cancer medicament and has excellent prospects in development and application. The use of Houttuynoid B in preparing the medicament for treating the pancreatic cancer involved in the invention is disclosed for the first time; the framework type of Houttuynoid B is a brand new framework type and Houttuynoid B has an unexpectedly high inhibition activity for pancreatic cancer cells.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid B, relate in particular to the application of Houttuynoid B in the anti-cancer of pancreas medicine of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid B that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid B that the present invention relates in preparation treatment cancer of pancreas medicine, because framework types belongs to brand-new framework types, and its inhibition for pancreatic cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously cancer of pancreas obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid B in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid B in the anti-cancer of pancreas medicine of preparation, and the structural formula of Houttuynoid B is shown in formula I:
The present invention finds by external MTT anti-tumor activity evaluation, and Houttuynoid B also has significant inhibitory action to the growth of human pancreas cancer cell strain PANC-1 and BXPC-3, suppresses the IC of this 2 strain Growth of Cells
50Value is respectively 1.11 ± 0.17 μ M and 1.43 ± 0.21 μ M.Therefore, Houttuynoid B can for the preparation of anti-cancer of pancreas medicine, have good development prospect.
Belong to open first for the purposes of the Houttuynoid B that the present invention relates in preparation treatment cancer of pancreas medicine, because framework types belongs to brand-new framework types, and its inhibition for pancreatic cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously cancer of pancreas obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid B involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid B tablet involved in the present invention:
Get 20 and digest compound Houttuynoid B, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid B capsule involved in the present invention:
Get 20 and digest compound Houttuynoid B, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Houttuynoid B to the growth inhibited effect of human pancreas cancer cell strain
1. method: the cell that is in the growth logarithmic (log) phase: human pancreas cancer cell strain PANC-1 and BXPC-3(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid B of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5 mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Houttuynoid B has significant inhibitory action to the growth of human pancreas cancer cell strain PANC-1 and BXPC-3.This chemical compound suppresses the IC of human pancreas cancer cell strain PANC-1 and BXPC-3 growth
50Value is respectively 1.11 ± 0.17 μ M and 1.43 ± 0.21 μ M.
Shown by above-described embodiment, Houttuynoid B of the present invention has good inhibitory action to the growth of human pancreas cancer cell strain PANC-1 and BXPC-3.Prove thus, it is active that Houttuynoid B of the present invention has anti-cancer of pancreas, can be for the preparation of anti-cancer of pancreas medicine.
Claims (1)
1.Houttuynoid the application of B in treatment cancer of pancreas medicine, described compound H outtuynoid B structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210419443 CN102872122B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid B in medicament for treating pancreatic cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210419443 CN102872122B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid B in medicament for treating pancreatic cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872122A true CN102872122A (en) | 2013-01-16 |
| CN102872122B CN102872122B (en) | 2013-05-15 |
Family
ID=47473793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210419443 Active CN102872122B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid B in medicament for treating pancreatic cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872122B (en) |
-
2012
- 2012-10-27 CN CN 201210419443 patent/CN102872122B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| CHEN, SHAO-DAN等: "Houttuynoids A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata", 《ORGANIC LETTERS》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872122B (en) | 2013-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872089B (en) | Application of Houttuynoid E in preparing medicines for treating skin cancer | |
| CN102872122B (en) | Application of Houttuynoid B in medicament for treating pancreatic cancer | |
| CN102872093B (en) | Application of Houttuynoid E in medicine for treating pancreatic cancer | |
| CN102872111B (en) | Application of Houttuynoid C in medicament for treating pancreatic cancer | |
| CN102861059B (en) | Application of Houttuynoid D in pancreatic cancer treatment medicine | |
| CN102872139B (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN102872112B (en) | Application of Houttuynoid A in medicament for treating bladder cancer | |
| CN102872123B (en) | Application of Houttuynoid C in medicament for treating bladder cancer | |
| CN102872121B (en) | Application of Houttuynoid C in medicament for treating laryngocarcinoma | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN102872134B (en) | Application of Houttuynoid D in drug for treating laryngocarcinoma | |
| CN102872144B (en) | Application of Houttuynoid D in drug for treating bladder cancer | |
| CN102872137B (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN102861050A (en) | Application of Houttuynoid A in medicine for treating pancreatic cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102872125B (en) | Application of Houttuynoid C in medicament for treating cervical cancer | |
| CN102872148B (en) | Application of Houttuynoid D in medicament for treating tongue cancer | |
| CN102872110B (en) | Application of Houttuynoid D in medicament for treating breast cancer | |
| CN103356535A (en) | Application of Sarcaboside A in preparation of drug for treating pancreatic cancer | |
| CN102872119A (en) | Application of Houttuynoid D in medicament for treating colorectal cancer | |
| CN102872117A (en) | Application of Houttuynoid D in medicament for treating gastric cancer | |
| CN102872116A (en) | Application of Houttuynoid D in medicament for treating liver cancer | |
| CN103463032A (en) | Application of Lycojaponicumin A in medicine for treating pancreatic cancer | |
| CN102872135A (en) | Application of Houttuynoid D in drug for treating renal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: LIU JUN Free format text: FORMER OWNER: WU JUNHUA Effective date: 20130606 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130606 Address after: 226400, No. 3, Hui Hui Road, dug Town, Rudong County, Jiangsu, Nantong Patentee after: Liu Jun Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |